Cullinan Therapeutics Inc (CGEM) ニュース

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) --  Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan...

Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines

CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Cullinan to provide clinical data updates on three novel targeted oncology programs and complete enrollment in...

Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023

Five abstracts accepted for poster presentation at the Society for Immunotherapy of Cancer 2023 Annual Meeting...

Cullinan Oncology to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan...